Clinical Trial Update: A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of itacitinib (INCB039110) in combination with ibrutinib in relapsed/refractory diffuse large B-cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-15